Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vobramitamab duocarmazine - MacroGenics

Next Previous
Search
Drug Profile

Vobramitamab duocarmazine - MacroGenics

Alternative Names: Anti-B7-H3 antibody drug conjugate - MacroGenics; B7-H3; MGC 018

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer; Small cell lung cancer
  • Preclinical Neuroblastoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 23 Jan 2025 MacroGenics completes the phase II Tamarack trial in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in the US, Australia, Belgium, France, Italy, South Korea, Poland, Spain and the United Kingdom (NCT05551117)
  • 05 Nov 2024 MacroGenics paused a phase I trial in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05293496)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top